Involvement of RARα and of PML-RARα in the differentiation response of ATRA-resistant cells upon treatment by SERCA inhibitors in combination with ATRA
| . | NB4-306 . | NB4-007/6 . | NB4-R1 . | NB4-R2 . |
|---|---|---|---|---|
| Description | ||||
| PML-RARα | mRNA, no protein | mRNA, no protein | Less protein | Inactivating mutation |
| RARα | Normal | Normal | Normal | Inactivating mutation |
| Differentiation (NBT) | Partially rescued | Partially rescued | Partially rescued | No rescue |
| Stabilization | ||||
| PML-RARα | = | = | + | = |
| RARα | + | + | = | = |
| . | NB4-306 . | NB4-007/6 . | NB4-R1 . | NB4-R2 . |
|---|---|---|---|---|
| Description | ||||
| PML-RARα | mRNA, no protein | mRNA, no protein | Less protein | Inactivating mutation |
| RARα | Normal | Normal | Normal | Inactivating mutation |
| Differentiation (NBT) | Partially rescued | Partially rescued | Partially rescued | No rescue |
| Stabilization | ||||
| PML-RARα | = | = | + | = |
| RARα | + | + | = | = |
Description of defects in PML-RARα and RARα in ATRA-resistant NB4-derived cell lines and results of treatments by ATRA in combination with tBHQ on (1) levels of differentiation determined by NBT-reducing activity and (2) protection of PML-RARα and RARα proteins from proteolytic degradation as examined by immunoblotting. = indicates not modified; and +, protected.